Functional significance of a C→A polymorphism in intron I of the cytochrome P450 CYP1A2 gene tested with caffeine

British Journal of Clinical Pharmacology

Volumn 47, Issue 4, 1999, Pages 445-449

  Sachse, Christoph ^a   Brockmöller, Jürgen ^a   Bauer, Steffen ^a   Roots, Ivar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Caffeine test; CYP1A2; Cytochrome P450 1A2; Enzyme induction; Gene polymorphism

Indexed keywords

CAFFEINE; CARCINOGEN; PARAXANTHINE; PHENACETIN O DEETHYLASE;

ARTICLE; CAUCASIAN; CONTROLLED STUDY; DNA SEQUENCE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN EXPERIMENT; INTRON; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; SMOKING; URINALYSIS;

CAFFEINE; CYTOCHROME P-450 CYP1A2; HUMANS; INTRONS; POLYMORPHISM, GENETIC; SMOKING;

EID: 0032908778     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00898.x     Document Type: Article

References (18)

1. 1 Bertz RJ, Grannemann GR. Use of in vitro data and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210-258.
2. 2 Coleman T, Ellis SW, Martin IJ, Lennard MS, Tucker GT. 1-Methyl 4 phenyl 1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4-implications for susceptibility to Parkinson's disease. J Pharmacol Exp Ther 1996; 277: 685-690.
3. 3 Gooderham NJ, Murray S, Lynch AM, et al. Heterocydic amines: evaluation of their role in diet associated human cancer. Br J Clin Pharmacol 1996; 42: 91-98.
4. 4 Catteau A, Bechtel YC, Poisson N, Beehtel PR, Bonaiti-Pellie C. A population and family study of CYP1A2 using caffeine urinary metabolites. Eur J Clin Pharmacol 1995; 47: 423-430.
5. 5 Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991; 50: 508-519.
6. 6 Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 1994; 4: 109-116.
7. 7 Eaton DI., Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogencsis: implications for human variability in expression and enzyme activity. Pharmacogenetics 1995; 5: 259-274.
8. 8 Rost KL, Brösicke H, Brockmöller J, Scheffler M, Helge H, Roots I, Increase of cytochrome P4501A2 activity by omeprazole: evidence by the 13C-[N-3-methyl|-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1992; 52: 170-180.
9. 9 MacLeod S, Sinha R, Kadlubar FF, Lang NP. Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2. Mutat Res 1997; 376: 135-142.
10. 10 Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 1994; 3: 413-421.
11. 11 Yokoi T, Sawada M, Kamataki T. Polymorphic drug metabolism: studies with recombinant Chinese hamster cells and analyses in human populations. Pharmacogenetics 1995; 5: S65-S69.
12. 12 MacLeod SL, Tang Y-M, Yokoi, et al. The role of recently discovered genetic polymorphism in the regulation of the human CYP1A2 gene. Proceedings of the American Association for Cancer Research 1998; 39: 396.
13. 13 Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 1984; 52: 459-464.
14. 14 Butler MA, Lang NP, Young JF, et al. Determination of CY1MA2 and NAT2 phenotypes in human populations by-analysis of caffeine urinary metabolites. Pharmacogenetics 1992; 2: 116-127.
15. 15 Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 1996; 6: 121-149.
16. 16 Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989.
17. 17 Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura S. Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol Endocrinol 1989; 3: 1399-1408.
18. 18 Daly AK, Brockmöller J, Broly F, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6: 193-201.